FLT3 and acute myeloid leukemia: In addition to it’s role as a marker of prognosis for AML patients (Kottaridis et al. 2001; Kottaridis et al. 2002) FLT3 has been used as a target for a humanized antibody (Li et al. 2004) which has been shown to have anti-FLT3 effects on leukemic cell lines in vitro and in xenograft models.